SIMILAR PATTERNS OF AMINO ACIDS FOR 5HIE_C_P06C801_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	5	VAL A 209 ALA A 220 LYS A 222 THR A 266 ASP A 332	None	0.60A	5hieC-1k9aA: 27.0	5hieC-1k9aA: 23.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1kbz	DTDP-GLUCOSE OXIDOREDUCTASE (Salmonella enterica)	PF04321 (RmlD_sub_bind)	6	GLY A 10 GLY A 7 VAL A 12 ALA A 193 LEU A 20 THR A 196	None	1.49A	5hieC-1kbzA: undetectable	5hieC-1kbzA: 21.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	GLY A 212 VAL A 219 ALA A 230 LYS A 232 LEU A 260 ASP A 351	None PY1 A 700 ( 4.7A) PY1 A 700 (-3.5A) PY1 A 700 (-3.9A) PY1 A 700 (-4.2A) PY1 A 700 (-2.7A)	0.92A	5hieC-1py5A: 25.6	5hieC-1py5A: 29.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 596 VAL A 603 ALA A 621 LYS A 623 THR A 670	None STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.7A) STI A 3 (-3.2A)	0.40A	5hieC-1t46A: 23.3	5hieC-1t46A: 30.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	GLY A 35 VAL A 42 ALA A 55 LYS A 57 GLY A 168 ASP A 169	None	0.87A	5hieC-1u5qA: 23.9	5hieC-1u5qA: 31.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 16 GLY A 18 VAL A 23 ALA A 36 LYS A 38 ASP A 148	HYM A 400 ( 3.8A) HYM A 400 ( 3.7A) HYM A 400 (-4.3A) HYM A 400 (-3.5A) HYM A 400 (-3.2A) HYM A 400 (-3.9A)	0.84A	5hieC-1zltA: 14.6	5hieC-1zltA: 25.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY X 18 VAL X 25 ALA X 37 LYS X 39 THR X 82 ASP X 148	STU X 902 ( 3.7A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-3.1A) STU X 902 (-4.1A) STU X 902 (-3.6A)	0.76A	5hieC-2dq7X: 26.6	5hieC-2dq7X: 33.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	5	GLY A 274 VAL A 281 ALA A 293 LYS A 295 THR A 338	H8H A 534 ( 3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-3.7A) H8H A 534 (-3.1A)	0.39A	5hieC-2h8hA: 26.4	5hieC-2h8hA: 22.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	GLY A 274 GLY A 276 VAL A 281 ALA A 293 LYS A 295 THR A 338	QUE A 1 ( 4.2A) None QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None QUE A 1 (-3.3A)	0.94A	5hieC-2hckA: 26.8	5hieC-2hckA: 23.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 249 GLY A 383 VAL A 256 ALA A 269 LYS A 271 THR A 315	None None GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.4A)	0.87A	5hieC-2hz0A: 26.6	5hieC-2hz0A: 29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 250 VAL A 256 ALA A 269 LYS A 271 THR A 315 ASP A 381	None GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.4A) GIN A 600 (-4.9A)	0.87A	5hieC-2hz0A: 26.6	5hieC-2hz0A: 29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 383 VAL A 256 ALA A 269 LYS A 271 THR A 315 ASP A 381	None GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.4A) GIN A 600 (-4.9A)	0.76A	5hieC-2hz0A: 26.6	5hieC-2hz0A: 29.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 589 VAL A 596 ALA A 614 LYS A 616 THR A 663 GLY A 795	None	0.71A	5hieC-2ogvA: 18.6	5hieC-2ogvA: 28.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 798 ALA A 614 LYS A 616 THR A 663 GLY A 795 ASP A 796	None	1.07A	5hieC-2ogvA: 18.6	5hieC-2ogvA: 28.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 798 VAL A 596 ALA A 614 LYS A 616 THR A 663 GLY A 795	None	0.72A	5hieC-2ogvA: 18.6	5hieC-2ogvA: 28.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 199 VAL A 204 ALA A 215 LYS A 217 LEU A 245 THR A 265	None ADE A 488 ( 4.9A) ADE A 488 (-3.2A) None ADE A 488 ( 4.5A) ADE A 488 (-4.3A)	0.60A	5hieC-2qluA: 26.1	5hieC-2qluA: 28.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 204 ALA A 215 LYS A 217 LEU A 245 THR A 265 ASP A 339	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) None ADE A 488 ( 4.5A) ADE A 488 (-4.3A) None	0.58A	5hieC-2qluA: 26.1	5hieC-2qluA: 28.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 725 VAL A 732 ALA A 749 LYS A 751 THR A 796 ASP A 861	None GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 (-4.0A) GW7 A 1 (-4.1A)	1.11A	5hieC-2r4bA: 26.7	5hieC-2r4bA: 30.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A1003 GLY A1005 VAL A1010 ALA A1028 LYS A1030 GLY A1149	S91 A 1 ( 3.9A) None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None	0.70A	5hieC-2z8cA: 26.7	5hieC-2z8cA: 32.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	VAL A 209 ALA A 220 LYS A 222 THR A 266 ASP A 332	None	0.60A	5hieC-3d7uA: 27.8	5hieC-3d7uA: 29.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 695 VAL A 702 ALA A 719 LYS A 721 THR A 766	ITI A 1 ( 4.8A) ITI A 1 (-4.8A) ITI A 1 (-2.9A) ITI A 1 (-2.6A) ITI A 1 (-3.8A)	0.58A	5hieC-3lzbA: 26.5	5hieC-3lzbA: 27.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	6	GLY A 211 GLY A 213 PHE A 233 VAL A 218 ALA A 229 THR A 279	LDN A 1 ( 4.7A) LDN A 1 ( 4.4A) None LDN A 1 ( 4.8A) LDN A 1 (-3.6A) LDN A 1 (-3.8A)	1.19A	5hieC-3mdyA: 26.2	5hieC-3mdyA: 29.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	7	GLY A 211 GLY A 213 VAL A 218 ALA A 229 LEU A 259 THR A 279 ASP A 350	LDN A 1 ( 4.7A) LDN A 1 ( 4.4A) LDN A 1 ( 4.8A) LDN A 1 (-3.6A) None LDN A 1 (-3.8A) LDN A 1 (-3.9A)	0.96A	5hieC-3mdyA: 26.2	5hieC-3mdyA: 29.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	7	GLY A 211 VAL A 218 ALA A 229 LYS A 231 LEU A 259 THR A 279 ASP A 350	LDN A 1 ( 4.7A) LDN A 1 ( 4.8A) LDN A 1 (-3.6A) None None LDN A 1 (-3.8A) LDN A 1 (-3.9A)	1.01A	5hieC-3mdyA: 26.2	5hieC-3mdyA: 29.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 209 GLY A 214 PHE A 231 VAL A 216 ALA A 227 THR A 277	None None None LDN A 600 (-4.5A) LDN A 600 (-3.2A) LDN A 600 (-4.0A)	1.42A	5hieC-3my0A: 25.0	5hieC-3my0A: 28.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 209 PHE A 231 VAL A 216 ALA A 227 LEU A 257 THR A 277	None None LDN A 600 (-4.5A) LDN A 600 (-3.2A) None LDN A 600 (-4.0A)	0.80A	5hieC-3my0A: 25.0	5hieC-3my0A: 28.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 209 VAL A 216 ALA A 227 LYS A 229 LEU A 257 THR A 277	None LDN A 600 (-4.5A) LDN A 600 (-3.2A) LDN A 600 (-4.0A) None LDN A 600 (-4.0A)	0.52A	5hieC-3my0A: 25.0	5hieC-3my0A: 28.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nk7	23S RRNA METHYLTRANSFERASE (Streptomyces actuosus)	PF00588 (SpoU_methylase) PF04705 (TSNR_N)	6	GLY A 47 VAL A 48 ALA A 100 LEU A 161 THR A 32 GLY A 166	None	1.40A	5hieC-3nk7A: undetectable	5hieC-3nk7A: 22.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	GLY A 356 GLY A 358 VAL A 363 ALA A 373 LEU A 406 THR A 421 TRP A 423 PHE A 475 GLY A 485	SM5 A 1 ( 4.9A) None SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 (-4.4A) SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None	0.78A	5hieC-3omvA: 34.8	5hieC-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 358 ALA A 373 LYS A 375 LEU A 406 THR A 421 PHE A 475 GLY A 485	None SM5 A 1 (-3.6A) SM5 A 1 (-3.5A) None SM5 A 1 (-4.4A) SM5 A 1 (-3.0A) None	0.89A	5hieC-3omvA: 34.8	5hieC-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3omv	RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 363 ALA A 373 LEU A 406 TRP A 423 PHE A 475 GLY A 485 ASP A 486	SM5 A 1 (-4.0A) SM5 A 1 (-3.6A) None SM5 A 1 (-4.3A) SM5 A 1 (-3.0A) None SM5 A 1 (-3.5A)	1.17A	5hieC-3omvA: 34.8	5hieC-3omvA: 77.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 201 VAL A 206 ALA A 217 LEU A 247 THR A 267	None TAK A 2 ( 4.9A) TAK A 2 (-3.5A) None TAK A 2 (-3.5A)	0.57A	5hieC-3q4tA: 25.9	5hieC-3q4tA: 30.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 201 VAL A 206 ALA A 217 LYS A 219 LEU A 247 THR A 267	None TAK A 2 ( 4.9A) TAK A 2 (-3.5A) TAK A 2 (-2.9A) None TAK A 2 (-3.5A)	1.49A	5hieC-3q4tA: 25.9	5hieC-3q4tA: 30.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 206 ALA A 217 LYS A 219 LEU A 247 THR A 267 ASP A 340	TAK A 2 ( 4.9A) TAK A 2 (-3.5A) TAK A 2 (-2.9A) None TAK A 2 (-3.5A) None	0.82A	5hieC-3q4tA: 25.9	5hieC-3q4tA: 30.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	5	VAL A 71 ALA A 84 LYS A 86 THR A 144 ASP A 211	ANP A1634 (-4.1A) ANP A1634 (-3.6A) ANP A1634 (-3.1A) ANP A1634 (-4.6A) MG A 529 (-2.2A)	0.58A	5hieC-3q5iA: 20.6	5hieC-3q5iA: 22.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qat	MALONYL COA-ACYL CARRIER PROTEIN TRANSACYLASE (Bartonella henselae)	PF00698 (Acyl_transf_1)	6	GLY A 300 GLY A 278 PHE A 7 VAL A 299 ALA A 308 LEU A 81	None	1.40A	5hieC-3qatA: undetectable	5hieC-3qatA: 18.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	GLY B 596 ALA B 616 LYS B 618 PHE B 942 GLY B 952 ASP B 953	None	0.87A	5hieC-3qd2B: 22.0	5hieC-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	GLY B 596 VAL B 603 ALA B 616 PHE B 942 GLY B 952 ASP B 953	None	0.83A	5hieC-3qd2B: 22.0	5hieC-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	GLY B 599 ALA B 616 LYS B 618 PHE B 942 GLY B 952 ASP B 953	None	0.55A	5hieC-3qd2B: 22.0	5hieC-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qd2	EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	GLY B 599 VAL B 603 ALA B 616 PHE B 942 GLY B 952 ASP B 953	None	0.63A	5hieC-3qd2B: 22.0	5hieC-3qd2B: 26.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3qfv	CDC42BPB PROTEIN (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 83 VAL A 90 ALA A 103 LYS A 105 ASP A 218	NM7 A 416 (-3.0A) NM7 A 416 (-3.7A) NM7 A 416 ( 3.7A) EDO A 417 (-3.5A) EDO A 417 (-3.7A)	0.52A	5hieC-3qfvA: 20.8	5hieC-3qfvA: 23.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3r3g	THROMBIN HEAVY CHAIN (Homo sapiens)	PF00089 (Trypsin)	6	GLY B 197 GLY B 211 VAL B 213 ALA B 190 LEU B 160 GLY B 136	None	1.39A	5hieC-3r3gB: undetectable	5hieC-3r3gB: 19.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3she	MAP KINASE-ACTIVATED PROTEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 51 GLY A 53 VAL A 58 ALA A 71 LYS A 73 ASP A 187	I85 A 350 (-3.5A) I85 A 350 (-3.1A) I85 A 350 (-4.9A) I85 A 350 (-3.3A) I85 A 350 (-2.8A) I85 A 350 (-3.3A)	0.78A	5hieC-3sheA: 19.9	5hieC-3sheA: 26.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 424 GLY A 426 VAL A 431 ALA A 443 LYS A 445 THR A 489	PP2 A 1 ( 4.1A) PP2 A 1 ( 4.8A) PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 (-4.5A) PP2 A 1 (-3.3A)	0.69A	5hieC-3sxsA: 26.8	5hieC-3sxsA: 31.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4a4l	SERINE/THREONINE-PRO TEIN KINASE PLK1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 60 ALA A 80 LYS A 82 PHE A 183 GLY A 193 ASP A 194	939 A1331 ( 4.7A) 939 A1331 (-3.5A) 939 A1331 (-2.6A) 939 A1331 (-4.0A) None 939 A1331 (-3.1A)	0.82A	5hieC-4a4lA: 20.4	5hieC-4a4lA: 27.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4a4l	SERINE/THREONINE-PRO TEIN KINASE PLK1 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 60 GLY A 62 ALA A 80 LYS A 82 PHE A 183 GLY A 193	939 A1331 ( 4.7A) 939 A1331 ( 3.7A) 939 A1331 (-3.5A) 939 A1331 (-2.6A) 939 A1331 (-4.0A) None	0.83A	5hieC-4a4lA: 20.4	5hieC-4a4lA: 27.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw2	SERINE/THREONINE-PRO TEIN KINASE MRCK ALPHA (Rattus norvegicus)	PF00069 (Pkinase) PF00433 (Pkinase_C)	5	GLY A 84 VAL A 91 ALA A 104 LYS A 106 ASP A 219	None None EDO A1420 (-3.4A) EDO A1419 (-3.3A) None	0.61A	5hieC-4aw2A: 20.4	5hieC-4aw2A: 20.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 98 GLY A 100 VAL A 105 ALA A 121 LYS A 123 THR A 169	30K A1365 ( 3.9A) 30K A1365 ( 4.4A) 30K A1365 ( 4.6A) 30K A1365 (-3.2A) 30K A1365 (-3.8A) 30K A1365 (-3.8A)	0.85A	5hieC-4aw5A: 26.9	5hieC-4aw5A: 31.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	GLY A 215 PHE A 237 VAL A 222 ALA A 233 LEU A 263 THR A 283	None None TAK A1507 (-4.7A) TAK A1507 (-3.3A) FLC A1503 ( 4.5A) TAK A1507 (-3.6A)	0.79A	5hieC-4c02A: 5.3	5hieC-4c02A: 28.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	GLY A 215 VAL A 222 ALA A 233 LYS A 235 LEU A 263 THR A 283	None TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 ( 4.5A) FLC A1503 ( 4.5A) TAK A1507 (-3.6A)	0.47A	5hieC-4c02A: 5.3	5hieC-4c02A: 28.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4cfh	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1 (Rattus norvegicus)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	6	GLY A 23 GLY A 25 VAL A 30 ALA A 43 LYS A 45 ASP A 157	STU A1550 (-3.1A) STU A1550 (-3.8A) None STU A1550 (-3.1A) STU A1550 (-3.6A) STU A1550 (-3.6A)	1.09A	5hieC-4cfhA: 23.8	5hieC-4cfhA: 23.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 617 VAL A 624 ALA A 653 LYS A 655 THR A 701	None DI1 A1000 (-4.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.9A) DI1 A1000 (-3.6A)	0.58A	5hieC-4ckrA: 24.9	5hieC-4ckrA: 31.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f0g	SERINE/THREONINE-PRO TEIN KINASE ROCO4 (Dictyostelium discoideum)	PF07714 (Pkinase_Tyr)	6	GLY A1033 GLY A1035 PHE A1037 VAL A1040 ALA A1053 LYS A1055	None	1.06A	5hieC-4f0gA: 26.6	5hieC-4f0gA: 30.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f0g	SERINE/THREONINE-PRO TEIN KINASE ROCO4 (Dictyostelium discoideum)	PF07714 (Pkinase_Tyr)	6	GLY A1033 PHE A1037 VAL A1040 ALA A1053 LYS A1055 PHE A1161	None	1.07A	5hieC-4f0gA: 26.6	5hieC-4f0gA: 30.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	GLY A 856 GLY A 858 VAL A 863 ALA A 880 LYS A 882 GLY A 993	IZA A2001 ( 4.9A) IZA A2001 ( 3.7A) None IZA A2001 (-3.4A) IZA A2001 ( 4.7A) None	0.78A	5hieC-4gl9A: 25.6	5hieC-4gl9A: 29.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	GLY A 856 VAL A 863 ALA A 880 LYS A 882 GLY A 993 ASP A 994	IZA A2001 ( 4.9A) None IZA A2001 (-3.4A) IZA A2001 ( 4.7A) None IZA A2001 ( 4.5A)	0.97A	5hieC-4gl9A: 25.6	5hieC-4gl9A: 29.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	6	GLY A 133 GLY A 135 VAL A 140 ALA A 156 LYS A 158 THR A 205	None	0.69A	5hieC-4hzsA: 19.4	5hieC-4hzsA: 29.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	6	GLY A 133 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 269	None	0.73A	5hieC-4hzsA: 19.4	5hieC-4hzsA: 29.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 133 VAL A 140 ALA A 156 LYS A 158 THR A 205 GLY A 269	1G0 A 401 ( 4.2A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.7A) 1G0 A 401 (-3.2A) None	0.64A	5hieC-4id7A: 26.2	5hieC-4id7A: 30.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4idt	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 407 GLY A 409 VAL A 414 ALA A 427 LYS A 429 ASP A 534	T28 A 701 ( 3.6A) T28 A 701 ( 3.0A) T28 A 701 (-4.7A) T28 A 701 (-3.0A) T28 A 701 ( 3.8A) T28 A 701 ( 3.4A)	0.94A	5hieC-4idtA: 24.4	5hieC-4idtA: 24.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4j7b	POLO-LIKE KINASE (Danio rerio)	PF00069 (Pkinase)	6	GLY A 48 ALA A 66 LYS A 68 PHE A 169 GLY A 179 ASP A 180	None	1.15A	5hieC-4j7bA: 23.2	5hieC-4j7bA: 27.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4l52	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7, TGF-BETA-ACTIVATED KINASE 1 AND MAP3K7-BINDING PROTEIN 1 CHIMERA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 43 GLY A 45 PHE A 47 VAL A 50 LYS A 63 ASP A 175	1UL A 501 ( 4.1A) 1UL A 501 ( 3.7A) None 1UL A 501 ( 4.9A) None 1UL A 501 (-4.2A)	0.66A	5hieC-4l52A: 21.7	5hieC-4l52A: 29.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4l52	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7, TGF-BETA-ACTIVATED KINASE 1 AND MAP3K7-BINDING PROTEIN 1 CHIMERA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 43 GLY A 45 VAL A 50 ALA A 61 LYS A 63 ASP A 175	1UL A 501 ( 4.1A) 1UL A 501 ( 3.7A) 1UL A 501 ( 4.9A) 1UL A 501 (-3.1A) None 1UL A 501 (-4.2A)	0.82A	5hieC-4l52A: 21.7	5hieC-4l52A: 29.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	GLY A 29 GLY A 31 VAL A 36 ALA A 49 LYS A 51 LEU A 150	ANP A 401 (-3.8A) ANP A 401 (-3.4A) ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-2.9A) ANP A 401 (-4.8A)	1.28A	5hieC-4m69A: 26.8	5hieC-4m69A: 27.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	GLY A 29 GLY A 31 VAL A 36 ALA A 49 LYS A 51 THR A 95	ANP A 401 (-3.8A) ANP A 401 (-3.4A) ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-2.9A) ANP A 401 (-3.8A)	0.66A	5hieC-4m69A: 26.8	5hieC-4m69A: 27.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	6	GLY A 29 VAL A 36 ALA A 49 LYS A 51 LEU A 74 THR A 95	ANP A 401 (-3.8A) ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-2.9A) None ANP A 401 (-3.8A)	0.72A	5hieC-4m69A: 26.8	5hieC-4m69A: 27.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 54 ALA A 67 LYS A 69 THR A 123 ASP A 191	None SIN A 401 ( 3.7A) None None None	0.55A	5hieC-4o38A: 20.0	5hieC-4o38A: 26.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 596 GLY A 598 VAL A 603 LYS A 642 THR A 687	2TT A1201 (-3.3A) 2TT A1201 ( 4.4A) 2TT A1201 (-4.2A) 2TT A1201 ( 4.6A) None	0.50A	5hieC-4oliA: 26.0	5hieC-4oliA: 20.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 904 GLY A 906 VAL A 911 ALA A 928 GLY A1040 ASP A1041	2TT A1202 ( 4.2A) 2TT A1202 ( 3.8A) 2TT A1202 (-4.5A) 2TT A1202 ( 3.9A) 2TT A1202 (-3.4A) 2TT A1202 (-4.6A)	0.83A	5hieC-4oliA: 26.0	5hieC-4oliA: 20.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 904 GLY A 906 VAL A 911 ALA A 928 LYS A 930 ASP A1041	2TT A1202 ( 4.2A) 2TT A1202 ( 3.8A) 2TT A1202 (-4.5A) 2TT A1202 ( 3.9A) None 2TT A1202 (-4.6A)	0.77A	5hieC-4oliA: 26.0	5hieC-4oliA: 20.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rew	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1 (Homo sapiens)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	6	GLY A 25 GLY A 27 VAL A 32 ALA A 45 LYS A 47 ASP A 159	STU A 601 (-3.5A) STU A 601 (-3.4A) STU A 601 ( 4.8A) STU A 601 (-3.2A) STU A 601 ( 3.7A) STU A 601 (-3.7A)	0.94A	5hieC-4rewA: 23.8	5hieC-4rewA: 20.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	5	GLY A 15 VAL A 22 ALA A 35 LYS A 37 THR A 81	ACP A1264 ( 4.2A) ACP A1264 (-4.7A) ACP A1264 (-2.9A) None ACP A1264 (-4.5A)	0.52A	5hieC-4ueuA: 26.9	5hieC-4ueuA: 34.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4uy9	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 151 GLY A 153 VAL A 158 ALA A 169 LYS A 171 ASP A 294	None	0.98A	5hieC-4uy9A: 27.6	5hieC-4uy9A: 30.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	5	GLY A 409 GLY A 411 VAL A 416 ALA A 428 THR A 474	746 A 702 ( 3.5A) 746 A 702 (-3.0A) 746 A 702 ( 4.3A) 746 A 702 (-2.4A) 746 A 702 (-3.7A)	0.43A	5hieC-4y93A: 27.6	5hieC-4y93A: 23.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 470 VAL A 477 ALA A 488 LYS A 490 THR A 539 ASP A 606	4CV A 801 ( 3.9A) None 4CV A 801 (-3.5A) 4CV A 801 (-3.9A) 4CV A 801 (-2.8A) 4CV A 801 (-3.5A)	0.98A	5hieC-4yffA: 25.7	5hieC-4yffA: 31.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ynz	SERINE/THREONINE-PRO TEIN KINASE BRSK2 (Mus musculus)	PF00069 (Pkinase)	5	GLY A 27 VAL A 34 ALA A 47 LYS A 49 LEU A 80	None	0.46A	5hieC-4ynzA: 22.1	5hieC-4ynzA: 26.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5d7a	TRAF2 AND NCK-INTERACTING PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 32 GLY A 34 VAL A 39 ALA A 52 LYS A 54 ASP A 171	GLY A 32 ( 0.0A) GLY A 34 ( 0.0A) VAL A 39 (-0.6A) ALA A 52 (-0.0A) LYS A 54 ( 0.0A) ASP A 171 ( 0.5A)	0.83A	5hieC-5d7aA: 25.8	5hieC-5d7aA: 30.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 251 GLY A 253 VAL A 258 ALA A 275 LYS A 277 LEU A 305 THR A 325	STU A 601 (-2.9A) STU A 601 ( 3.9A) STU A 601 (-4.0A) STU A 601 (-3.1A) STU A 601 (-2.4A) STU A 601 ( 3.8A) STU A 601 ( 3.7A)	0.83A	5hieC-5e8yA: 25.3	5hieC-5e8yA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 251 PHE A 279 VAL A 258 ALA A 275 LYS A 277 LEU A 305 THR A 325	STU A 601 (-2.9A) None STU A 601 (-4.0A) STU A 601 (-3.1A) STU A 601 (-2.4A) STU A 601 ( 3.8A) STU A 601 ( 3.7A)	1.10A	5hieC-5e8yA: 25.3	5hieC-5e8yA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	GLY A 251 VAL A 258 ALA A 275 LYS A 277 LEU A 305 THR A 325 ASP A 397	STU A 601 (-2.9A) STU A 601 (-4.0A) STU A 601 (-3.1A) STU A 601 (-2.4A) STU A 601 ( 3.8A) STU A 601 ( 3.7A) STU A 601 (-3.0A)	0.64A	5hieC-5e8yA: 25.3	5hieC-5e8yA: 28.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	5	GLY A 100 VAL A 107 ALA A 120 LYS A 122 LEU A 154	5U5 A 401 (-3.8A) 5U5 A 401 ( 4.3A) 5U5 A 401 (-3.5A) 5U5 A 401 (-2.6A) 5U5 A 401 (-4.8A)	0.55A	5hieC-5eykA: 22.7	5hieC-5eykA: 25.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 904 VAL A 911 ALA A 928 LYS A 930 GLY A1040 ASP A1041	5U3 A1200 ( 3.7A) 5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) None 5U3 A1200 ( 4.9A) 5U3 A1200 ( 4.9A)	0.70A	5hieC-5f1zA: 26.8	5hieC-5f1zA: 29.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fd2	SERINE/THREONINE-PRO TEIN KINASE B-RAF (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	GLY A 464 VAL A 471 ALA A 481 LYS A 483 LEU A 514 THR A 529 TRP A 531 PHE A 583 GLY A 593	None 5XJ A 801 (-4.6A) 5XJ A 801 (-3.1A) 5XJ A 801 (-3.8A) 5XJ A 801 (-4.5A) 5XJ A 801 (-3.4A) 5XJ A 801 (-4.4A) 5XJ A 801 (-4.3A) 5XJ A 801 ( 3.7A)	0.51A	5hieC-5fd2A: 35.1	5hieC-5fd2A: 97.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fd2	SERINE/THREONINE-PRO TEIN KINASE B-RAF (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 471 ALA A 481 LYS A 483 LEU A 514 THR A 529 TRP A 531 PHE A 583 GLY A 593 ASP A 594	5XJ A 801 (-4.6A) 5XJ A 801 (-3.1A) 5XJ A 801 (-3.8A) 5XJ A 801 (-4.5A) 5XJ A 801 (-3.4A) 5XJ A 801 (-4.4A) 5XJ A 801 (-4.3A) 5XJ A 801 ( 3.7A) None	0.70A	5hieC-5fd2A: 35.1	5hieC-5fd2A: 97.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 600 VAL A 607 ALA A 625 LYS A 627 THR A 674	None 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-4.0A) 748 A1001 (-3.2A)	0.46A	5hieC-5grnA: 21.1	5hieC-5grnA: 28.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hes	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 28 VAL A 30 ALA A 43 LYS A 45 THR A 82 ASP A 151	None 032 A 401 (-4.4A) 032 A 401 (-3.2A) 032 A 401 (-4.4A) 032 A 401 (-3.7A) 032 A 401 (-4.6A)	0.91A	5hieC-5hesA: 20.6	5hieC-5hesA: 31.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5o2c	SERINE/THREONINE-PRO TEIN KINASE WNK3 (Homo sapiens)	PF00069 (Pkinase) PF12202 (OSR1_C)	6	GLY A 154 VAL A 161 ALA A 174 THR A 227 PHE A 282 GLY A 293	None None GOL A 604 ( 3.8A) GOL A 604 (-3.9A) GOL A 604 ( 4.5A) GOL A 604 ( 4.6A)	0.73A	5hieC-5o2cA: 24.8	5hieC-5o2cA: 27.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5okt	CASEIN KINASE I ISOFORM DELTA (Homo sapiens)	no annotation	6	GLY C 16 GLY C 18 PHE C 20 ALA C 36 LYS C 38 ASP C 149	None None None 9XK C 301 ( 3.7A) 9XK C 301 ( 4.6A) None	0.90A	5hieC-5oktC: 20.7	5hieC-5oktC: 21.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5to3	PROTHROMBIN,THROMBOM ODULIN (Homo sapiens)	PF00089 (Trypsin) PF09064 (Tme5_EGF_like)	6	GLY B 222 GLY B 238 VAL B 240 ALA B 215 LEU B 180 GLY B 151	None None None 0G6 B 501 (-3.4A) None None	1.37A	5hieC-5to3B: undetectable	5hieC-5to3B: 19.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 117 VAL A 124 ALA A 137 THR A 187 PHE A 240 GLY A 250	H8H A 401 ( 3.7A) H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None	0.75A	5hieC-5vcxA: 21.2	5hieC-5vcxA: 27.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 124 ALA A 137 THR A 187 PHE A 240 GLY A 250 ASP A 251	H8H A 401 (-4.7A) H8H A 401 (-3.3A) H8H A 401 (-3.5A) H8H A 401 (-4.3A) None EDO A 402 ( 2.9A)	0.81A	5hieC-5vcxA: 21.2	5hieC-5vcxA: 27.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vdk	WEE1-LIKE PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 219 GLY A 221 VAL A 226 ALA A 239 PHE A 346 GLY A 379	8X7 A 501 ( 3.8A) 8X7 A 501 (-3.4A) 8X7 A 501 ( 4.5A) 8X7 A 501 ( 3.7A) 8X7 A 501 (-3.7A) None	0.81A	5hieC-5vdkA: 22.4	5hieC-5vdkA: 29.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vil	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5 (Homo sapiens)	no annotation	6	GLY A 687 GLY A 689 VAL A 694 ALA A 707 LYS A 709 ASP A 822	9E1 A1001 ( 3.4A) 9E1 A1001 (-2.9A) 9E1 A1001 ( 4.0A) 9E1 A1001 (-3.5A) 9E1 A1001 (-2.8A) 9E1 A1001 (-3.6A)	0.82A	5hieC-5vilA: 4.7	5hieC-5vilA: 13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	6	GLY A 27 VAL A 32 ALA A 45 LYS A 47 LEU A 79 THR A 95	None 9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) 9WS A 401 (-3.3A) 9WS A 401 (-4.9A) 9WS A 401 (-3.2A)	0.72A	5hieC-5w5jA: 26.9	5hieC-5w5jA: 29.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	6	GLY A 892 GLY A 894 VAL A 899 ALA A 917 LYS A 919 THR A 963	ANP A1201 ( 3.8A) ANP A1201 (-2.8A) ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-3.8A) ANP A1201 (-3.9A)	0.87A	5hieC-5wnoA: 25.5	5hieC-5wnoA: 14.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	6	GLY A 892 PHE A 921 VAL A 899 ALA A 917 LEU A 947 THR A 963	ANP A1201 ( 3.8A) None ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-4.7A) ANP A1201 (-3.9A)	1.17A	5hieC-5wnoA: 25.5	5hieC-5wnoA: 14.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5x1t	PPKA-294 (Serratia sp. FS14)	no annotation	6	GLY A 30 GLY A 35 VAL A 37 ALA A 50 LEU A 102 THR A 118	ADP A 401 (-3.4A) None ADP A 401 ( 4.5A) ADP A 401 (-3.4A) None ADP A 401 (-4.1A)	1.20A	5hieC-5x1tA: 21.4	5hieC-5x1tA: 13.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5x1t	PPKA-294 (Serratia sp. FS14)	no annotation	6	GLY A 35 PHE A 86 VAL A 37 ALA A 50 LEU A 102 THR A 118	None None ADP A 401 ( 4.5A) ADP A 401 (-3.4A) None ADP A 401 (-4.1A)	1.32A	5hieC-5x1tA: 21.4	5hieC-5x1tA: 13.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xqo	PCRGLX PROTEIN (Penicillium chrysogenum)	no annotation	6	GLY A 377 GLY A 360 ALA A 291 LEU A 409 PHE A 401 GLY A 408	None	1.29A	5hieC-5xqoA: undetectable	5hieC-5xqoA: 14.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cth	CONCANAVALIN A-LIKE LECTIN PROTEIN KINASE FAMILY PROTEIN (Theobroma cacao)	no annotation	6	GLY A 276 PHE A 280 VAL A 283 ALA A 296 LYS A 298 GLY A 410	FE7 A 601 ( 3.7A) None FE7 A 601 ( 4.3A) FE7 A 601 (-3.3A) FE7 A 601 (-3.6A) FE7 A 601 ( 4.1A)	0.76A	5hieC-6cthA: 22.7	5hieC-6cthA: 13.91

[["5HIE_C_P06C801_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",5,"VAL A 209;ALA A 220;LYS A 222;THR A 266;ASP A 332","None","0.60A","5hieC-1k9aA:27.0","5hieC-1k9aA:23.09"],["5HIE_C_P06C801_1","1kbz","Salmonella enterica","DTDP-GLUCOSE OXIDOREDUCTASE","PF04321(RmlD_sub_bind)",6,"GLY A  10;GLY A   7;VAL A  12;ALA A 193;LEU A  20;THR A 196","None","1.49A","5hieC-1kbzA:undetectable","5hieC-1kbzA:21.75"],["5HIE_C_P06C801_1","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"GLY A 212;VAL A 219;ALA A 230;LYS A 232;LEU A 260;ASP A 351","None;PY1 A 700 ( 4.7A);PY1 A 700 (-3.5A);PY1 A 700 (-3.9A);PY1 A 700 (-4.2A);PY1 A 700 (-2.7A)","0.92A","5hieC-1py5A:25.6","5hieC-1py5A:29.86"],["5HIE_C_P06C801_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",5,"GLY A 596;VAL A 603;ALA A 621;LYS A 623;THR A 670","None;STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.7A);STI A   3 (-3.2A)","0.40A","5hieC-1t46A:23.3","5hieC-1t46A:30.77"],["5HIE_C_P06C801_1","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"GLY A  35;VAL A  42;ALA A  55;LYS A  57;GLY A 168;ASP A 169","None","0.87A","5hieC-1u5qA:23.9","5hieC-1u5qA:31.27"],["5HIE_C_P06C801_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",6,"GLY A  16;GLY A  18;VAL A  23;ALA A  36;LYS A  38;ASP A 148","HYM A 400 ( 3.8A);HYM A 400 ( 3.7A);HYM A 400 (-4.3A);HYM A 400 (-3.5A);HYM A 400 (-3.2A);HYM A 400 (-3.9A)","0.84A","5hieC-1zltA:14.6","5hieC-1zltA:25.98"],["5HIE_C_P06C801_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",6,"GLY X  18;VAL X  25;ALA X  37;LYS X  39;THR X  82;ASP X 148","STU X 902 ( 3.7A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-3.1A);STU X 902 (-4.1A);STU X 902 (-3.6A)","0.76A","5hieC-2dq7X:26.6","5hieC-2dq7X:33.44"],["5HIE_C_P06C801_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",5,"GLY A 274;VAL A 281;ALA A 293;LYS A 295;THR A 338","H8H A 534 ( 3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-3.7A);H8H A 534 (-3.1A)","0.39A","5hieC-2h8hA:26.4","5hieC-2h8hA:22.00"],["5HIE_C_P06C801_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"GLY A 274;GLY A 276;VAL A 281;ALA A 293;LYS A 295;THR A 338","QUE A   1 ( 4.2A);None;QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;QUE A   1 (-3.3A)","0.94A","5hieC-2hckA:26.8","5hieC-2hckA:23.97"],["5HIE_C_P06C801_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"GLY A 249;GLY A 383;VAL A 256;ALA A 269;LYS A 271;THR A 315","None;None;GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.4A)","0.87A","5hieC-2hz0A:26.6","5hieC-2hz0A:29.08"],["5HIE_C_P06C801_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"GLY A 250;VAL A 256;ALA A 269;LYS A 271;THR A 315;ASP A 381","None;GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.4A);GIN A 600 (-4.9A)","0.87A","5hieC-2hz0A:26.6","5hieC-2hz0A:29.08"],["5HIE_C_P06C801_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"GLY A 383;VAL A 256;ALA A 269;LYS A 271;THR A 315;ASP A 381","None;GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.4A);GIN A 600 (-4.9A)","0.76A","5hieC-2hz0A:26.6","5hieC-2hz0A:29.08"],["5HIE_C_P06C801_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",6,"GLY A 589;VAL A 596;ALA A 614;LYS A 616;THR A 663;GLY A 795","None","0.71A","5hieC-2ogvA:18.6","5hieC-2ogvA:28.05"],["5HIE_C_P06C801_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",6,"GLY A 798;ALA A 614;LYS A 616;THR A 663;GLY A 795;ASP A 796","None","1.07A","5hieC-2ogvA:18.6","5hieC-2ogvA:28.05"],["5HIE_C_P06C801_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",6,"GLY A 798;VAL A 596;ALA A 614;LYS A 616;THR A 663;GLY A 795","None","0.72A","5hieC-2ogvA:18.6","5hieC-2ogvA:28.05"],["5HIE_C_P06C801_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"GLY A 199;VAL A 204;ALA A 215;LYS A 217;LEU A 245;THR A 265","None;ADE A 488 ( 4.9A);ADE A 488 (-3.2A);None;ADE A 488 ( 4.5A);ADE A 488 (-4.3A)","0.60A","5hieC-2qluA:26.1","5hieC-2qluA:28.11"],["5HIE_C_P06C801_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",6,"VAL A 204;ALA A 215;LYS A 217;LEU A 245;THR A 265;ASP A 339","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);None;ADE A 488 ( 4.5A);ADE A 488 (-4.3A);None","0.58A","5hieC-2qluA:26.1","5hieC-2qluA:28.11"],["5HIE_C_P06C801_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"GLY A 725;VAL A 732;ALA A 749;LYS A 751;THR A 796;ASP A 861","None;GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 (-4.0A);GW7 A   1 (-4.1A)","1.11A","5hieC-2r4bA:26.7","5hieC-2r4bA:30.54"],["5HIE_C_P06C801_1","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"GLY A1003;GLY A1005;VAL A1010;ALA A1028;LYS A1030;GLY A1149","S91 A   1 ( 3.9A);None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None","0.70A","5hieC-2z8cA:26.7","5hieC-2z8cA:32.38"],["5HIE_C_P06C801_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",5,"VAL A 209;ALA A 220;LYS A 222;THR A 266;ASP A 332","None","0.60A","5hieC-3d7uA:27.8","5hieC-3d7uA:29.21"],["5HIE_C_P06C801_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"GLY A 695;VAL A 702;ALA A 719;LYS A 721;THR A 766","ITI A   1 ( 4.8A);ITI A   1 (-4.8A);ITI A   1 (-2.9A);ITI A   1 (-2.6A);ITI A   1 (-3.8A)","0.58A","5hieC-3lzbA:26.5","5hieC-3lzbA:27.14"],["5HIE_C_P06C801_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",6,"GLY A 211;GLY A 213;PHE A 233;VAL A 218;ALA A 229;THR A 279","LDN A   1 ( 4.7A);LDN A   1 ( 4.4A);None;LDN A   1 ( 4.8A);LDN A   1 (-3.6A);LDN A   1 (-3.8A)","1.19A","5hieC-3mdyA:26.2","5hieC-3mdyA:29.89"],["5HIE_C_P06C801_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",7,"GLY A 211;GLY A 213;VAL A 218;ALA A 229;LEU A 259;THR A 279;ASP A 350","LDN A   1 ( 4.7A);LDN A   1 ( 4.4A);LDN A   1 ( 4.8A);LDN A   1 (-3.6A);None;LDN A   1 (-3.8A);LDN A   1 (-3.9A)","0.96A","5hieC-3mdyA:26.2","5hieC-3mdyA:29.89"],["5HIE_C_P06C801_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",7,"GLY A 211;VAL A 218;ALA A 229;LYS A 231;LEU A 259;THR A 279;ASP A 350","LDN A   1 ( 4.7A);LDN A   1 ( 4.8A);LDN A   1 (-3.6A);None;None;LDN A   1 (-3.8A);LDN A   1 (-3.9A)","1.01A","5hieC-3mdyA:26.2","5hieC-3mdyA:29.89"],["5HIE_C_P06C801_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",6,"GLY A 209;GLY A 214;PHE A 231;VAL A 216;ALA A 227;THR A 277","None;None;None;LDN A 600 (-4.5A);LDN A 600 (-3.2A);LDN A 600 (-4.0A)","1.42A","5hieC-3my0A:25.0","5hieC-3my0A:28.88"],["5HIE_C_P06C801_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",6,"GLY A 209;PHE A 231;VAL A 216;ALA A 227;LEU A 257;THR A 277","None;None;LDN A 600 (-4.5A);LDN A 600 (-3.2A);None;LDN A 600 (-4.0A)","0.80A","5hieC-3my0A:25.0","5hieC-3my0A:28.88"],["5HIE_C_P06C801_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",6,"GLY A 209;VAL A 216;ALA A 227;LYS A 229;LEU A 257;THR A 277","None;LDN A 600 (-4.5A);LDN A 600 (-3.2A);LDN A 600 (-4.0A);None;LDN A 600 (-4.0A)","0.52A","5hieC-3my0A:25.0","5hieC-3my0A:28.88"],["5HIE_C_P06C801_1","3nk7","Streptomyces actuosus","23S RRNA METHYLTRANSFERASE","PF00588(SpoU_methylase);PF04705(TSNR_N)",6,"GLY A  47;VAL A  48;ALA A 100;LEU A 161;THR A  32;GLY A 166","None","1.40A","5hieC-3nk7A:undetectable","5hieC-3nk7A:22.12"],["5HIE_C_P06C801_1","3omv","Homo sapiens","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",9,"GLY A 356;GLY A 358;VAL A 363;ALA A 373;LEU A 406;THR A 421;TRP A 423;PHE A 475;GLY A 485","SM5 A   1 ( 4.9A);None;SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 (-4.4A);SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None","0.78A","5hieC-3omvA:34.8","5hieC-3omvA:77.85"],["5HIE_C_P06C801_1","3omv","Homo sapiens","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",7,"GLY A 358;ALA A 373;LYS A 375;LEU A 406;THR A 421;PHE A 475;GLY A 485","None;SM5 A   1 (-3.6A);SM5 A   1 (-3.5A);None;SM5 A   1 (-4.4A);SM5 A   1 (-3.0A);None","0.89A","5hieC-3omvA:34.8","5hieC-3omvA:77.85"],["5HIE_C_P06C801_1","3omv","Homo sapiens","RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",7,"VAL A 363;ALA A 373;LEU A 406;TRP A 423;PHE A 475;GLY A 485;ASP A 486","SM5 A   1 (-4.0A);SM5 A   1 (-3.6A);None;SM5 A   1 (-4.3A);SM5 A   1 (-3.0A);None;SM5 A   1 (-3.5A)","1.17A","5hieC-3omvA:34.8","5hieC-3omvA:77.85"],["5HIE_C_P06C801_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",5,"GLY A 201;VAL A 206;ALA A 217;LEU A 247;THR A 267","None;TAK A   2 ( 4.9A);TAK A   2 (-3.5A);None;TAK A   2 (-3.5A)","0.57A","5hieC-3q4tA:25.9","5hieC-3q4tA:30.92"],["5HIE_C_P06C801_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",6,"GLY A 201;VAL A 206;ALA A 217;LYS A 219;LEU A 247;THR A 267","None;TAK A   2 ( 4.9A);TAK A   2 (-3.5A);TAK A   2 (-2.9A);None;TAK A   2 (-3.5A)","1.49A","5hieC-3q4tA:25.9","5hieC-3q4tA:30.92"],["5HIE_C_P06C801_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",6,"VAL A 206;ALA A 217;LYS A 219;LEU A 247;THR A 267;ASP A 340","TAK A   2 ( 4.9A);TAK A   2 (-3.5A);TAK A   2 (-2.9A);None;TAK A   2 (-3.5A);None","0.82A","5hieC-3q4tA:25.9","5hieC-3q4tA:30.92"],["5HIE_C_P06C801_1","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",5,"VAL A  71;ALA A  84;LYS A  86;THR A 144;ASP A 211","ANP A1634 (-4.1A);ANP A1634 (-3.6A);ANP A1634 (-3.1A);ANP A1634 (-4.6A); MG A 529 (-2.2A)","0.58A","5hieC-3q5iA:20.6","5hieC-3q5iA:22.14"],["5HIE_C_P06C801_1","3qat","Bartonella henselae","MALONYL COA-ACYL CARRIER PROTEIN TRANSACYLASE","PF00698(Acyl_transf_1)",6,"GLY A 300;GLY A 278;PHE A   7;VAL A 299;ALA A 308;LEU A  81","None","1.40A","5hieC-3qatA:undetectable","5hieC-3qatA:18.58"],["5HIE_C_P06C801_1","3qd2","Mus musculus","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","PF00069(Pkinase)",6,"GLY B 596;ALA B 616;LYS B 618;PHE B 942;GLY B 952;ASP B 953","None","0.87A","5hieC-3qd2B:22.0","5hieC-3qd2B:26.13"],["5HIE_C_P06C801_1","3qd2","Mus musculus","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","PF00069(Pkinase)",6,"GLY B 596;VAL B 603;ALA B 616;PHE B 942;GLY B 952;ASP B 953","None","0.83A","5hieC-3qd2B:22.0","5hieC-3qd2B:26.13"],["5HIE_C_P06C801_1","3qd2","Mus musculus","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","PF00069(Pkinase)",6,"GLY B 599;ALA B 616;LYS B 618;PHE B 942;GLY B 952;ASP B 953","None","0.55A","5hieC-3qd2B:22.0","5hieC-3qd2B:26.13"],["5HIE_C_P06C801_1","3qd2","Mus musculus","EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 3","PF00069(Pkinase)",6,"GLY B 599;VAL B 603;ALA B 616;PHE B 942;GLY B 952;ASP B 953","None","0.63A","5hieC-3qd2B:22.0","5hieC-3qd2B:26.13"],["5HIE_C_P06C801_1","3qfv","Homo sapiens","CDC42BPB PROTEIN","PF00069(Pkinase)",5,"GLY A  83;VAL A  90;ALA A 103;LYS A 105;ASP A 218","NM7 A 416 (-3.0A);NM7 A 416 (-3.7A);NM7 A 416 ( 3.7A);EDO A 417 (-3.5A);EDO A 417 (-3.7A)","0.52A","5hieC-3qfvA:20.8","5hieC-3qfvA:23.11"],["5HIE_C_P06C801_1","3r3g","Homo sapiens","THROMBIN HEAVY CHAIN","PF00089(Trypsin)",6,"GLY B 197;GLY B 211;VAL B 213;ALA B 190;LEU B 160;GLY B 136","None","1.39A","5hieC-3r3gB:undetectable","5hieC-3r3gB:19.87"],["5HIE_C_P06C801_1","3she","Homo sapiens","MAP KINASE-ACTIVATED PROTEIN KINASE 3","PF00069(Pkinase)",6,"GLY A  51;GLY A  53;VAL A  58;ALA A  71;LYS A  73;ASP A 187","I85 A 350 (-3.5A);I85 A 350 (-3.1A);I85 A 350 (-4.9A);I85 A 350 (-3.3A);I85 A 350 (-2.8A);I85 A 350 (-3.3A)","0.78A","5hieC-3sheA:19.9","5hieC-3sheA:26.18"],["5HIE_C_P06C801_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",6,"GLY A 424;GLY A 426;VAL A 431;ALA A 443;LYS A 445;THR A 489","PP2 A   1 ( 4.1A);PP2 A   1 ( 4.8A);PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 (-4.5A);PP2 A   1 (-3.3A)","0.69A","5hieC-3sxsA:26.8","5hieC-3sxsA:31.27"],["5HIE_C_P06C801_1","4a4l","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK1","PF00069(Pkinase)",6,"GLY A  60;ALA A  80;LYS A  82;PHE A 183;GLY A 193;ASP A 194","939 A1331 ( 4.7A);939 A1331 (-3.5A);939 A1331 (-2.6A);939 A1331 (-4.0A);None;939 A1331 (-3.1A)","0.82A","5hieC-4a4lA:20.4","5hieC-4a4lA:27.30"],["5HIE_C_P06C801_1","4a4l","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK1","PF00069(Pkinase)",6,"GLY A  60;GLY A  62;ALA A  80;LYS A  82;PHE A 183;GLY A 193","939 A1331 ( 4.7A);939 A1331 ( 3.7A);939 A1331 (-3.5A);939 A1331 (-2.6A);939 A1331 (-4.0A);None","0.83A","5hieC-4a4lA:20.4","5hieC-4a4lA:27.30"],["5HIE_C_P06C801_1","4aw2","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE MRCK ALPHA","PF00069(Pkinase);PF00433(Pkinase_C)",5,"GLY A  84;VAL A  91;ALA A 104;LYS A 106;ASP A 219","None;None;EDO A1420 (-3.4A);EDO A1419 (-3.3A);None","0.61A","5hieC-4aw2A:20.4","5hieC-4aw2A:20.32"],["5HIE_C_P06C801_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",6,"GLY A  98;GLY A 100;VAL A 105;ALA A 121;LYS A 123;THR A 169","30K A1365 ( 3.9A);30K A1365 ( 4.4A);30K A1365 ( 4.6A);30K A1365 (-3.2A);30K A1365 (-3.8A);30K A1365 (-3.8A)","0.85A","5hieC-4aw5A:26.9","5hieC-4aw5A:31.38"],["5HIE_C_P06C801_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"GLY A 215;PHE A 237;VAL A 222;ALA A 233;LEU A 263;THR A 283","None;None;TAK A1507 (-4.7A);TAK A1507 (-3.3A);FLC A1503 ( 4.5A);TAK A1507 (-3.6A)","0.79A","5hieC-4c02A:5.3","5hieC-4c02A:28.74"],["5HIE_C_P06C801_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"GLY A 215;VAL A 222;ALA A 233;LYS A 235;LEU A 263;THR A 283","None;TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 ( 4.5A);FLC A1503 ( 4.5A);TAK A1507 (-3.6A)","0.47A","5hieC-4c02A:5.3","5hieC-4c02A:28.74"],["5HIE_C_P06C801_1","4cfh","Rattus norvegicus","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1","PF00069(Pkinase);PF16579(AdenylateSensor)",6,"GLY A  23;GLY A  25;VAL A  30;ALA A  43;LYS A  45;ASP A 157","STU A1550 (-3.1A);STU A1550 (-3.8A);None;STU A1550 (-3.1A);STU A1550 (-3.6A);STU A1550 (-3.6A)","1.09A","5hieC-4cfhA:23.8","5hieC-4cfhA:23.75"],["5HIE_C_P06C801_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",5,"GLY A 617;VAL A 624;ALA A 653;LYS A 655;THR A 701","None;DI1 A1000 (-4.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.9A);DI1 A1000 (-3.6A)","0.58A","5hieC-4ckrA:24.9","5hieC-4ckrA:31.10"],["5HIE_C_P06C801_1","4f0g","Dictyostelium discoideum","SERINE\/THREONINE-PROTEIN KINASE ROCO4","PF07714(Pkinase_Tyr)",6,"GLY A1033;GLY A1035;PHE A1037;VAL A1040;ALA A1053;LYS A1055","None","1.06A","5hieC-4f0gA:26.6","5hieC-4f0gA:30.56"],["5HIE_C_P06C801_1","4f0g","Dictyostelium discoideum","SERINE\/THREONINE-PROTEIN KINASE ROCO4","PF07714(Pkinase_Tyr)",6,"GLY A1033;PHE A1037;VAL A1040;ALA A1053;LYS A1055;PHE A1161","None","1.07A","5hieC-4f0gA:26.6","5hieC-4f0gA:30.56"],["5HIE_C_P06C801_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"GLY A 856;GLY A 858;VAL A 863;ALA A 880;LYS A 882;GLY A 993","IZA A2001 ( 4.9A);IZA A2001 ( 3.7A);None;IZA A2001 (-3.4A);IZA A2001 ( 4.7A);None","0.78A","5hieC-4gl9A:25.6","5hieC-4gl9A:29.61"],["5HIE_C_P06C801_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"GLY A 856;VAL A 863;ALA A 880;LYS A 882;GLY A 993;ASP A 994","IZA A2001 ( 4.9A);None;IZA A2001 (-3.4A);IZA A2001 ( 4.7A);None;IZA A2001 ( 4.5A)","0.97A","5hieC-4gl9A:25.6","5hieC-4gl9A:29.61"],["5HIE_C_P06C801_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",6,"GLY A 133;GLY A 135;VAL A 140;ALA A 156;LYS A 158;THR A 205","None","0.69A","5hieC-4hzsA:19.4","5hieC-4hzsA:29.94"],["5HIE_C_P06C801_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",6,"GLY A 133;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 269","None","0.73A","5hieC-4hzsA:19.4","5hieC-4hzsA:29.94"],["5HIE_C_P06C801_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",6,"GLY A 133;VAL A 140;ALA A 156;LYS A 158;THR A 205;GLY A 269","1G0 A 401 ( 4.2A);1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.7A);1G0 A 401 (-3.2A);None","0.64A","5hieC-4id7A:26.2","5hieC-4id7A:30.03"],["5HIE_C_P06C801_1","4idt","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14","PF00069(Pkinase)",6,"GLY A 407;GLY A 409;VAL A 414;ALA A 427;LYS A 429;ASP A 534","T28 A 701 ( 3.6A);T28 A 701 ( 3.0A);T28 A 701 (-4.7A);T28 A 701 (-3.0A);T28 A 701 ( 3.8A);T28 A 701 ( 3.4A)","0.94A","5hieC-4idtA:24.4","5hieC-4idtA:24.47"],["5HIE_C_P06C801_1","4j7b","Danio rerio","POLO-LIKE KINASE","PF00069(Pkinase)",6,"GLY A  48;ALA A  66;LYS A  68;PHE A 169;GLY A 179;ASP A 180","None","1.15A","5hieC-4j7bA:23.2","5hieC-4j7bA:27.91"],["5HIE_C_P06C801_1","4l52","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7, TGF-BETA-ACTIVATED KINASE 1 AND MAP3K7-BINDING PROTEIN 1 CHIMERA","PF07714(Pkinase_Tyr)",6,"GLY A  43;GLY A  45;PHE A  47;VAL A  50;LYS A  63;ASP A 175","1UL A 501 ( 4.1A);1UL A 501 ( 3.7A);None;1UL A 501 ( 4.9A);None;1UL A 501 (-4.2A)","0.66A","5hieC-4l52A:21.7","5hieC-4l52A:29.74"],["5HIE_C_P06C801_1","4l52","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7, TGF-BETA-ACTIVATED KINASE 1 AND MAP3K7-BINDING PROTEIN 1 CHIMERA","PF07714(Pkinase_Tyr)",6,"GLY A  43;GLY A  45;VAL A  50;ALA A  61;LYS A  63;ASP A 175","1UL A 501 ( 4.1A);1UL A 501 ( 3.7A);1UL A 501 ( 4.9A);1UL A 501 (-3.1A);None;1UL A 501 (-4.2A)","0.82A","5hieC-4l52A:21.7","5hieC-4l52A:29.74"],["5HIE_C_P06C801_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"GLY A  29;GLY A  31;VAL A  36;ALA A  49;LYS A  51;LEU A 150","ANP A 401 (-3.8A);ANP A 401 (-3.4A);ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-2.9A);ANP A 401 (-4.8A)","1.28A","5hieC-4m69A:26.8","5hieC-4m69A:27.98"],["5HIE_C_P06C801_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"GLY A  29;GLY A  31;VAL A  36;ALA A  49;LYS A  51;THR A  95","ANP A 401 (-3.8A);ANP A 401 (-3.4A);ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-2.9A);ANP A 401 (-3.8A)","0.66A","5hieC-4m69A:26.8","5hieC-4m69A:27.98"],["5HIE_C_P06C801_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"GLY A  29;VAL A  36;ALA A  49;LYS A  51;LEU A  74;THR A  95","ANP A 401 (-3.8A);ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-2.9A);None;ANP A 401 (-3.8A)","0.72A","5hieC-4m69A:26.8","5hieC-4m69A:27.98"],["5HIE_C_P06C801_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",5,"VAL A  54;ALA A  67;LYS A  69;THR A 123;ASP A 191","None;SIN A 401 ( 3.7A);None;None;None","0.55A","5hieC-4o38A:20.0","5hieC-4o38A:26.33"],["5HIE_C_P06C801_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",5,"GLY A 596;GLY A 598;VAL A 603;LYS A 642;THR A 687","2TT A1201 (-3.3A);2TT A1201 ( 4.4A);2TT A1201 (-4.2A);2TT A1201 ( 4.6A);None","0.50A","5hieC-4oliA:26.0","5hieC-4oliA:20.58"],["5HIE_C_P06C801_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"GLY A 904;GLY A 906;VAL A 911;ALA A 928;GLY A1040;ASP A1041","2TT A1202 ( 4.2A);2TT A1202 ( 3.8A);2TT A1202 (-4.5A);2TT A1202 ( 3.9A);2TT A1202 (-3.4A);2TT A1202 (-4.6A)","0.83A","5hieC-4oliA:26.0","5hieC-4oliA:20.58"],["5HIE_C_P06C801_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"GLY A 904;GLY A 906;VAL A 911;ALA A 928;LYS A 930;ASP A1041","2TT A1202 ( 4.2A);2TT A1202 ( 3.8A);2TT A1202 (-4.5A);2TT A1202 ( 3.9A);None;2TT A1202 (-4.6A)","0.77A","5hieC-4oliA:26.0","5hieC-4oliA:20.58"],["5HIE_C_P06C801_1","4rew","Homo sapiens","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1","PF00069(Pkinase);PF16579(AdenylateSensor)",6,"GLY A  25;GLY A  27;VAL A  32;ALA A  45;LYS A  47;ASP A 159","STU A 601 (-3.5A);STU A 601 (-3.4A);STU A 601 ( 4.8A);STU A 601 (-3.2A);STU A 601 ( 3.7A);STU A 601 (-3.7A)","0.94A","5hieC-4rewA:23.8","5hieC-4rewA:20.38"],["5HIE_C_P06C801_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",5,"GLY A  15;VAL A  22;ALA A  35;LYS A  37;THR A  81","ACP A1264 ( 4.2A);ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;ACP A1264 (-4.5A)","0.52A","5hieC-4ueuA:26.9","5hieC-4ueuA:34.19"],["5HIE_C_P06C801_1","4uy9","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF00069(Pkinase)",6,"GLY A 151;GLY A 153;VAL A 158;ALA A 169;LYS A 171;ASP A 294","None","0.98A","5hieC-4uy9A:27.6","5hieC-4uy9A:30.33"],["5HIE_C_P06C801_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",5,"GLY A 409;GLY A 411;VAL A 416;ALA A 428;THR A 474","746 A 702 ( 3.5A);746 A 702 (-3.0A);746 A 702 ( 4.3A);746 A 702 (-2.4A);746 A 702 (-3.7A)","0.43A","5hieC-4y93A:27.6","5hieC-4y93A:23.08"],["5HIE_C_P06C801_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",6,"GLY A 470;VAL A 477;ALA A 488;LYS A 490;THR A 539;ASP A 606","4CV A 801 ( 3.9A);None;4CV A 801 (-3.5A);4CV A 801 (-3.9A);4CV A 801 (-2.8A);4CV A 801 (-3.5A)","0.98A","5hieC-4yffA:25.7","5hieC-4yffA:31.29"],["5HIE_C_P06C801_1","4ynz","Mus musculus","SERINE\/THREONINE-PROTEIN KINASE BRSK2","PF00069(Pkinase)",5,"GLY A  27;VAL A  34;ALA A  47;LYS A  49;LEU A  80","None","0.46A","5hieC-4ynzA:22.1","5hieC-4ynzA:26.88"],["5HIE_C_P06C801_1","5d7a","Homo sapiens","TRAF2 AND NCK-INTERACTING PROTEIN KINASE","PF00069(Pkinase)",6,"GLY A  32;GLY A  34;VAL A  39;ALA A  52;LYS A  54;ASP A 171","GLY A  32 ( 0.0A);GLY A  34 ( 0.0A);VAL A  39 (-0.6A);ALA A  52 (-0.0A);LYS A  54 ( 0.0A);ASP A 171 ( 0.5A)","0.83A","5hieC-5d7aA:25.8","5hieC-5d7aA:30.89"],["5HIE_C_P06C801_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",7,"GLY A 251;GLY A 253;VAL A 258;ALA A 275;LYS A 277;LEU A 305;THR A 325","STU A 601 (-2.9A);STU A 601 ( 3.9A);STU A 601 (-4.0A);STU A 601 (-3.1A);STU A 601 (-2.4A);STU A 601 ( 3.8A);STU A 601 ( 3.7A)","0.83A","5hieC-5e8yA:25.3","5hieC-5e8yA:28.37"],["5HIE_C_P06C801_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",7,"GLY A 251;PHE A 279;VAL A 258;ALA A 275;LYS A 277;LEU A 305;THR A 325","STU A 601 (-2.9A);None;STU A 601 (-4.0A);STU A 601 (-3.1A);STU A 601 (-2.4A);STU A 601 ( 3.8A);STU A 601 ( 3.7A)","1.10A","5hieC-5e8yA:25.3","5hieC-5e8yA:28.37"],["5HIE_C_P06C801_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",7,"GLY A 251;VAL A 258;ALA A 275;LYS A 277;LEU A 305;THR A 325;ASP A 397","STU A 601 (-2.9A);STU A 601 (-4.0A);STU A 601 (-3.1A);STU A 601 (-2.4A);STU A 601 ( 3.8A);STU A 601 ( 3.7A);STU A 601 (-3.0A)","0.64A","5hieC-5e8yA:25.3","5hieC-5e8yA:28.37"],["5HIE_C_P06C801_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",5,"GLY A 100;VAL A 107;ALA A 120;LYS A 122;LEU A 154","5U5 A 401 (-3.8A);5U5 A 401 ( 4.3A);5U5 A 401 (-3.5A);5U5 A 401 (-2.6A);5U5 A 401 (-4.8A)","0.55A","5hieC-5eykA:22.7","5hieC-5eykA:25.53"],["5HIE_C_P06C801_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"GLY A 904;VAL A 911;ALA A 928;LYS A 930;GLY A1040;ASP A1041","5U3 A1200 ( 3.7A);5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);None;5U3 A1200 ( 4.9A);5U3 A1200 ( 4.9A)","0.70A","5hieC-5f1zA:26.8","5hieC-5f1zA:29.73"],["5HIE_C_P06C801_1","5fd2","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE B-RAF","PF07714(Pkinase_Tyr)",9,"GLY A 464;VAL A 471;ALA A 481;LYS A 483;LEU A 514;THR A 529;TRP A 531;PHE A 583;GLY A 593","None;5XJ A 801 (-4.6A);5XJ A 801 (-3.1A);5XJ A 801 (-3.8A);5XJ A 801 (-4.5A);5XJ A 801 (-3.4A);5XJ A 801 (-4.4A);5XJ A 801 (-4.3A);5XJ A 801 ( 3.7A)","0.51A","5hieC-5fd2A:35.1","5hieC-5fd2A:97.68"],["5HIE_C_P06C801_1","5fd2","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE B-RAF","PF07714(Pkinase_Tyr)",9,"VAL A 471;ALA A 481;LYS A 483;LEU A 514;THR A 529;TRP A 531;PHE A 583;GLY A 593;ASP A 594","5XJ A 801 (-4.6A);5XJ A 801 (-3.1A);5XJ A 801 (-3.8A);5XJ A 801 (-4.5A);5XJ A 801 (-3.4A);5XJ A 801 (-4.4A);5XJ A 801 (-4.3A);5XJ A 801 ( 3.7A);None","0.70A","5hieC-5fd2A:35.1","5hieC-5fd2A:97.68"],["5HIE_C_P06C801_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",5,"GLY A 600;VAL A 607;ALA A 625;LYS A 627;THR A 674","None;748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-4.0A);748 A1001 (-3.2A)","0.46A","5hieC-5grnA:21.1","5hieC-5grnA:28.77"],["5HIE_C_P06C801_1","5hes","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","PF07714(Pkinase_Tyr)",6,"GLY A  28;VAL A  30;ALA A  43;LYS A  45;THR A  82;ASP A 151","None;032 A 401 (-4.4A);032 A 401 (-3.2A);032 A 401 (-4.4A);032 A 401 (-3.7A);032 A 401 (-4.6A)","0.91A","5hieC-5hesA:20.6","5hieC-5hesA:31.59"],["5HIE_C_P06C801_1","5o2c","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE WNK3","PF00069(Pkinase);PF12202(OSR1_C)",6,"GLY A 154;VAL A 161;ALA A 174;THR A 227;PHE A 282;GLY A 293","None;None;GOL A 604 ( 3.8A);GOL A 604 (-3.9A);GOL A 604 ( 4.5A);GOL A 604 ( 4.6A)","0.73A","5hieC-5o2cA:24.8","5hieC-5o2cA:27.59"],["5HIE_C_P06C801_1","5okt","Homo sapiens","CASEIN KINASE I ISOFORM DELTA","no annotation",6,"GLY C  16;GLY C  18;PHE C  20;ALA C  36;LYS C  38;ASP C 149","None;None;None;9XK C 301 ( 3.7A);9XK C 301 ( 4.6A);None","0.90A","5hieC-5oktC:20.7","5hieC-5oktC:21.46"],["5HIE_C_P06C801_1","5to3","Homo sapiens","PROTHROMBIN,THROMBOMODULIN","PF00089(Trypsin);PF09064(Tme5_EGF_like)",6,"GLY B 222;GLY B 238;VAL B 240;ALA B 215;LEU B 180;GLY B 151","None;None;None;0G6 B 501 (-3.4A);None;None","1.37A","5hieC-5to3B:undetectable","5hieC-5to3B:19.04"],["5HIE_C_P06C801_1","5vcx","Homo sapiens","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","PF00069(Pkinase)",6,"GLY A 117;VAL A 124;ALA A 137;THR A 187;PHE A 240;GLY A 250","H8H A 401 ( 3.7A);H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None","0.75A","5hieC-5vcxA:21.2","5hieC-5vcxA:27.51"],["5HIE_C_P06C801_1","5vcx","Homo sapiens","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","PF00069(Pkinase)",6,"VAL A 124;ALA A 137;THR A 187;PHE A 240;GLY A 250;ASP A 251","H8H A 401 (-4.7A);H8H A 401 (-3.3A);H8H A 401 (-3.5A);H8H A 401 (-4.3A);None;EDO A 402 ( 2.9A)","0.81A","5hieC-5vcxA:21.2","5hieC-5vcxA:27.51"],["5HIE_C_P06C801_1","5vdk","Homo sapiens","WEE1-LIKE PROTEIN KINASE 2","PF00069(Pkinase)",6,"GLY A 219;GLY A 221;VAL A 226;ALA A 239;PHE A 346;GLY A 379","8X7 A 501 ( 3.8A);8X7 A 501 (-3.4A);8X7 A 501 ( 4.5A);8X7 A 501 ( 3.7A);8X7 A 501 (-3.7A);None","0.81A","5hieC-5vdkA:22.4","5hieC-5vdkA:29.28"],["5HIE_C_P06C801_1","5vil","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5","no annotation",6,"GLY A 687;GLY A 689;VAL A 694;ALA A 707;LYS A 709;ASP A 822","9E1 A1001 ( 3.4A);9E1 A1001 (-2.9A);9E1 A1001 ( 4.0A);9E1 A1001 (-3.5A);9E1 A1001 (-2.8A);9E1 A1001 (-3.6A)","0.82A","5hieC-5vilA:4.7","5hieC-5vilA:13.40"],["5HIE_C_P06C801_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",6,"GLY A  27;VAL A  32;ALA A  45;LYS A  47;LEU A  79;THR A  95","None;9WS A 401 ( 4.6A);9WS A 401 (-3.3A);9WS A 401 (-3.3A);9WS A 401 (-4.9A);9WS A 401 (-3.2A)","0.72A","5hieC-5w5jA:26.9","5hieC-5w5jA:29.22"],["5HIE_C_P06C801_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",6,"GLY A 892;GLY A 894;VAL A 899;ALA A 917;LYS A 919;THR A 963","ANP A1201 ( 3.8A);ANP A1201 (-2.8A);ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-3.8A);ANP A1201 (-3.9A)","0.87A","5hieC-5wnoA:25.5","5hieC-5wnoA:14.18"],["5HIE_C_P06C801_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",6,"GLY A 892;PHE A 921;VAL A 899;ALA A 917;LEU A 947;THR A 963","ANP A1201 ( 3.8A);None;ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-4.7A);ANP A1201 (-3.9A)","1.17A","5hieC-5wnoA:25.5","5hieC-5wnoA:14.18"],["5HIE_C_P06C801_1","5x1t","Serratia sp. FS14","PPKA-294","no annotation",6,"GLY A  30;GLY A  35;VAL A  37;ALA A  50;LEU A 102;THR A 118","ADP A 401 (-3.4A);None;ADP A 401 ( 4.5A);ADP A 401 (-3.4A);None;ADP A 401 (-4.1A)","1.20A","5hieC-5x1tA:21.4","5hieC-5x1tA:13.25"],["5HIE_C_P06C801_1","5x1t","Serratia sp. FS14","PPKA-294","no annotation",6,"GLY A  35;PHE A  86;VAL A  37;ALA A  50;LEU A 102;THR A 118","None;None;ADP A 401 ( 4.5A);ADP A 401 (-3.4A);None;ADP A 401 (-4.1A)","1.32A","5hieC-5x1tA:21.4","5hieC-5x1tA:13.25"],["5HIE_C_P06C801_1","5xqo","Penicillium chrysogenum","PCRGLX PROTEIN","no annotation",6,"GLY A 377;GLY A 360;ALA A 291;LEU A 409;PHE A 401;GLY A 408","None","1.29A","5hieC-5xqoA:undetectable","5hieC-5xqoA:14.98"],["5HIE_C_P06C801_1","6cth","Theobroma cacao","CONCANAVALIN A-LIKE LECTIN PROTEIN KINASE FAMILY PROTEIN","no annotation",6,"GLY A 276;PHE A 280;VAL A 283;ALA A 296;LYS A 298;GLY A 410","FE7 A 601 ( 3.7A);None;FE7 A 601 ( 4.3A);FE7 A 601 (-3.3A);FE7 A 601 (-3.6A);FE7 A 601 ( 4.1A)","0.76A","5hieC-6cthA:22.7","5hieC-6cthA:13.91"]]